Analysis of the pharmaceutical market of medicines in Ukraine used for herpes diseases

Authors

  • Олександр Котенко Національний фармацевтичний університет, Ukraine
  • Viktoriia Pul-Luzan National University of Pharmacy, Ukraine
  • Tetyana Yarnykh National University of Pharmacy, Ukraine
  • Anastasiia Tarasova National University of Pharmacy, Ukraine

DOI:

https://doi.org/10.5281/zenodo.7721588

Abstract

The topic of herpes is one of the acute problems of our time. It is very common among people all over the world, even in Ukraine the rate of people with herpes is very high. Herpes simplex virus type 1 (HSV-1) causes oral herpes, which appears mostly around the mouth and affects the surrounding skin. Herpes simplex virus type 2 (HSV-2) causes genital herpes. According to the World Health Organization (WHO), 67% of people under the age of 50 worldwide have HSV-1, and 13% of people have HSV-2. Herpes cannot be cured, but it is possible to alleviate the unpleasant sensations during the manifestations of this disease and reduce the likelihood of repeated outbreaks. The main requirement for herpes treatment is a combination of components that would provide an optimal therapeutic effect. The components of the medicinal product should have the following effect: antiviral, immunomodulating, anti-inflammatory, antimicrobial, the ability to stimulate skin regeneration, reduce itching and pain.

Author Biographies

Viktoriia Pul-Luzan , National University of Pharmacy

Associate Professor of the Department of Drug Technology of the National University of Pharmacy

Tetyana Yarnykh , National University of Pharmacy

Professor of the Department of Drug Technology of the National University of Pharmacy

Anastasiia Tarasova , National University of Pharmacy

5th year student of higher education of the National University of Pharmacy

References

European Health for All Statistical Database. Available from: http://medstat.gov.ua/ukr/normdoc.html.

Patil A., Goldust M., Wollina U. [Herpes zoster: A Review of Clinical Manifestations and Management]. Viruses. 2022; 14(2):192-198.

Mancuso R., Sicurella M., Agostini S., Marconi P., Clerici M. [Herpes simplex virus type 1 and Alzheimer’s disease: link and potential impact on treatment]. Expert Rev anti Infect Ther. 2019; 17(9): 715-731.

Dam C., Lede I., Schaar J., Al-Dulaimy M. [Herpes zoster after COVID vaccination]. Int J Infect Dis. 2021; 111: 169-171.

Cohen E., Jeng B. [Herpes Zoaster: a brief definitive review]. Cornea. 2021; 40 (8): 943-949.

Stadnytska N. Ye., Parashchyn Zh. D., Lobur I. P., Fito I.V. [Analysis of the unternal market of medicines used in diseases of the nasal cavity]. Pharmaceutical review. 2021; 2: 36-43.

State Register of Medicines of Ukraine. [Державний реєстр лікарських засобів України] Available from: http://www.drlz.kiev.ua/ Ukrainian.

Medicine Control. Available from: http://likicontrol.com.ua.

Published

2023-03-11

How to Cite

Котенко, О., Pul-Luzan , V. ., Yarnykh , T. ., & Tarasova , A. . (2023). Analysis of the pharmaceutical market of medicines in Ukraine used for herpes diseases. Annals of Mechnikov’s Institute, (1), 62–67. https://doi.org/10.5281/zenodo.7721588

Issue

Section

Research Articles